These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 27977392)

  • 41. Does Antihypertensive Drug Class Affect Day-to-Day Variability of Self-Measured Home Blood Pressure? The HOMED-BP Study.
    Asayama K; Ohkubo T; Hanazawa T; Watabe D; Hosaka M; Satoh M; Yasui D; Staessen JA; Imai Y;
    J Am Heart Assoc; 2016 Mar; 5(3):e002995. PubMed ID: 27009620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension.
    Mucalo I; Jovanovski E; Rahelić D; Božikov V; Romić Z; Vuksan V
    J Ethnopharmacol; 2013 Oct; 150(1):148-53. PubMed ID: 23973636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
    Tikkanen I; Chilton R; Johansen OE
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
    Zimdahl H; Haupt A; Brendel M; Bour L; Machicao F; Salsali A; Broedl UC; Woerle HJ; Häring HU; Staiger H
    Pharmacogenet Genomics; 2017 Apr; 27(4):135-142. PubMed ID: 28134748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Incidence of Antihypertensive Drug-induced Side Effects in Patients with Diabetes Mellitus Type 2 and Hypertension.
    Loga-Zec S; Asceric M; Loga-Andrijic N; Kapetanovic B; Zerem E
    Med Arch; 2014 Dec; 68(6):372-5. PubMed ID: 25648509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
    Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
    J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
    Oigman W; Gomes MA; Pereira-Barretto AC; Póvoa R; Kohlmann O; Rocha JC; Nobre F
    Clin Ther; 2013 May; 35(5):702-10. PubMed ID: 23623755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
    Yoon KH; Nishimura R; Lee J; Crowe S; Salsali A; Hach T; Woerle HJ
    Diabetes Obes Metab; 2016 Oct; 18(10):1045-9. PubMed ID: 27265507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study.
    Bronsert MR; Henderson WG; Valuck R; Hosokawa P; Hammermeister K
    J Am Board Fam Med; 2013; 26(5):529-38. PubMed ID: 24004705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
    Jünger C; Prochaska JH; Gori T; Schulz A; Binder H; Daiber A; Koeck T; Rapp S; Lackner KJ; Münzel T; Wild PS
    J Cardiovasc Med (Hagerstown); 2022 Mar; 23(3):191-197. PubMed ID: 34939776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
    Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
    Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.